XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add ...

Animal-derived serum and plasma from mostly cattle and pig carcasses is used in medical and life science research, including ...

A serum that promises to regrow hair in just 20 days sounds like a dream come true, but how much of it is backed by real ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...

Learn how firefighters exposed to major wildfires in California have changes in their immune system and inflammatory response ...

Hibiscus tea, green tea, oolong tea, and black tea are among the research-backed options that may help support healthy blood ...

Indian researchers identify blood markers for early diabetes and kidney risk, enabling personalized treatment and timely ...

Metavia, an affiliate of Dong-A ST, announced on November 11 that it presented additional analysis results from the Phase 2a clinical trial of ...

HOUSTON -- A conservative dialysis strategy improved rates of kidney function compared to conventional thrice-weekly dialysis ...